IndustryCompany release

Ardelyx Q3 revenue climbs 19% to $125.5M as IBSRELA sales grow

🇺🇸 Ardelyx, Inc. (ARDX) · Tue 03 Nov 2026

The US drugmaker reaffirmed its 2026 guidance and reported $285M in cash and investments, with Phase 3 ACCEL data for tenapanor in chronic idiopathic constipation due in the second half of 2027.

Ardelyx reported third-quarter 2026 results on 3 November, with combined revenue from IBSRELA and XPHOZAH of $125.5M, a 19% increase on the same period a year earlier.

IBSRELA, indicated for irritable bowel syndrome with constipation (IBS-C), brought in $96.3M. XPHOZAH, used for hyperphosphatemia in patients on dialysis, contributed $29.2M.

The company reaffirmed its 2026 guidance and ended the period with $285M in cash and investments. The headline for the update also refers to a $1B sales goal, which Ardelyx reaffirmed; the material available to us does not give further detail on its timing or basis.

Ardelyx also said topline data from the Phase 3 ACCEL programme, which is testing tenapanor in chronic idiopathic constipation, are expected in the second half of 2027.

What it means for your team

  • Market-access teams can note that both marketed products, IBSRELA in IBS-C and XPHOZAH in dialysis-related hyperphosphatemia, were reported as contributing to the quarter's revenue.
  • Unchanged 2026 guidance suggests no change in the company's near-term commercial outlook.
  • Regulatory teams tracking tenapanor should note that ACCEL topline data in chronic idiopathic constipation are not expected until 2H27, so any label-expansion filing would follow that readout.

Company's press release (SEC filing): Ardelyx, Inc. ↗

Article written by VigiEye from the official source (Ardelyx, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →